Study of a new drug combo for brca-mutated ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new combination of two investigational drugs for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that has a BRCA gene mutation. The goal is to see if the combination is safe and effective, and it might offer a new treatment option for your type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 19 and 75 years old.
- Have advanced (spread or come back) high-grade cancer of the ovary, fallopian tube, or the lining of the belly (primary peritoneal) with a BRCA gene mutation.
- Have a body mass index (BMI) between 18 and 28, to ensure a healthy weight range for the study.
- Not have a bowel disease (like Crohn's) or had bowel surgery that could interfere with how the oral drug is absorbed.
- Not have cancer spread to the brain unless it is stable after treatment.
- Not have had severe side effects from the study drug D215 in the past (like very low blood counts, cough, or taste changes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
This study tests whether a new targeted drug (distamab vedotin) combined with standard chemo (carboplatin) works better than chemo alone for women with advanced ovarian cancer that has high levels of HER2. It is for women who have not had chemotherapy yet and have already had surgery to remove the tumor.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new drug called ABBV901, given alone or with other anticancer drugs, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and how it affects the body.
This study tests a new combination treatment for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after at least two prior treatments. The aim is to see if this treatment can help shrink tumors and improve outcomes.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.